UK markets closed

Edwards Lifesciences Corporation (EW)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
104.65+0.79 (+0.76%)
As of 01:28PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 64.39B
Enterprise value 63.55B
Trailing P/E 44.96
Forward P/E 41.15
PEG ratio (5-yr expected) 3.43
Price/sales (ttm)12.22
Price/book (mrq)10.83
Enterprise value/revenue N/A
Enterprise value/EBITDA 33.17

Trading information

Stock price history

Beta (5Y monthly) 1.12
52-week change 3-7.08%
S&P500 52-week change 3-5.62%
52-week high 3131.73
52-week low 385.58
50-day moving average 397.84
200-day moving average 3109.43

Share statistics

Avg vol (3-month) 32.61M
Avg vol (10-day) 32.82M
Shares outstanding 5619.94M
Implied shares outstanding 6N/A
Float 8614.33M
% held by insiders 10.80%
% held by institutions 185.09%
Shares short (14 Jul 2022) 46.66M
Short ratio (14 Jul 2022) 42.65
Short % of float (14 Jul 2022) 41.08%
Short % of shares outstanding (14 Jul 2022) 41.07%
Shares short (prior month 14 Jun 2022) 45.87M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 23:1
Last split date 331 May 2020

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Jun 2022

Profitability

Profit margin 27.18%
Operating margin (ttm)30.75%

Management effectiveness

Return on assets (ttm)12.80%
Return on equity (ttm)26.28%

Income statement

Revenue (ttm)5.35B
Revenue per share (ttm)8.60
Quarterly revenue growth (yoy)-0.20%
Gross profit (ttm)3.98B
EBITDA 1.78B
Net income avi to common (ttm)1.46B
Diluted EPS (ttm)2.30
Quarterly earnings growth (yoy)-17.00%

Balance sheet

Total cash (mrq)1.52B
Total cash per share (mrq)2.44
Total debt (mrq)682.8M
Total debt/equity (mrq)11.49
Current ratio (mrq)3.37
Book value per share (mrq)9.59

Cash flow statement

Operating cash flow (ttm)1.53B
Levered free cash flow (ttm)1.1B